TD-5108 clinical trials
Also written TD-5108 and Velusetrag.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses TD-5108 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
Studies
Open first, then newest update. How each study uses TD-5108 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).CompletedPhase 2Alfasigma S.p.A.NCT05724069Written as Velusetrag 15 mg once daily for 4 weeks.How we know
- Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)CompletedPhase 2Alfasigma S.p.A.NCT00391820Written as TD-5108How we know
- Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly SubjectsCompletedPhase 1Alfasigma S.p.A.NCT01467726Written as VelusetragHow we know
- The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyCompletedPhase 2Theravance BiopharmaNCT02267525Written as VelusetragHow we know
- Phase 2 Study of Velusetrag in Diabetic or Idiopathic GastroparesisCompletedPhase 2Theravance BiopharmaNCT01718938Written as velusetrag dose 1How we know
Codes
What other systems call TD-5108 · ClinicalTrials.gg INT005365
- MeSH (NLM) C533727TD-5108One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533727 | TD-5108 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.